Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia.
about
Biomarkers of sepsisUtility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II scoreAn Elevated Glycemic Gap is Associated With Adverse Outcomes in Diabetic Patients With Community-Acquired PneumoniaPlasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia.Procalcitonin determined at emergency department as na early indicator of progression to septic shock in patient with sepsis associated with ureteral calculi.Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.Biomarkers for community-acquired pneumonia in the emergency department.Utility of Plasma Osteopontin Levels in Management of Community-Acquired Pneumonia.Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.Procalcitonin versus C-reactive protein: Usefulness as biomarker of sepsis in ICU patient.Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumoniaPrognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia.Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumoniaUsefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.Parameters of the Endocannabinoid System as Novel Biomarkers in Sepsis and Septic Shock.Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock.
P2860
Q26822575-B8CBBCCF-F2A5-4397-80A0-6EEAFEA78D6CQ34371462-8803B6F8-7F30-4FC6-804B-FD941504A5A2Q36153054-8A7CB915-FCA2-4BBB-BC0B-2DA0BF47CAC8Q36667012-3E0E5A47-FED2-4017-A885-78163F8EF378Q36912784-BC26728F-0556-4129-925A-B4D1C2DA7A7AQ37270551-E4BE947E-8B87-4FA3-93EB-2126D1847DB4Q38263097-D52796DD-32BC-4FBF-9CB2-134FE4D3301EQ40534344-91D21A29-D935-48E1-A8BF-78B9EEBD0276Q41172929-BE8B56AA-1E8C-4E35-A7F0-0F3D89321169Q41692073-5FFD7ACE-D72B-4BB0-9D49-8E444FA495D1Q41881166-744C7430-191D-494E-8668-167BE1C4D4A9Q41893491-6F3F5CAC-6BE9-4DA1-B46C-BCA98962C0EAQ42765865-C3C0AAA4-1D4E-46F6-9DFD-6803F165F08CQ44504198-9642C565-5492-4639-AE7D-5482B952FB18Q47153305-3D6FAA60-A423-4BB4-A046-06A30D6F2664Q55256161-F13D5F1E-82A7-4782-9DA6-838ABC41159D
P2860
Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@ast
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@en
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@nl
type
label
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@ast
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@en
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@nl
prefLabel
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@ast
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@en
Procalcitonin, C-reactive prot ...... atients with severe pneumonia.
@nl
P2093
P1476
Procalcitonin, C-reactive prot ...... patients with severe pneumonia
@en
P2093
F Krummenauer
Z F Forycki
P304
P356
10.1046/J.1469-0691.2002.00349.X
P577
2002-02-01T00:00:00Z